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A B S T R A C T
Topic: Brain tumor cell invasion and metastasis: anatomical, 
biological and clinical considerations
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Local infiltration and distal dissemination of tumor cells hamper efficacy of current treatments against central nervous system 
(CNS) tumors and greatly influence mortality and therapy-induced long-term morbidity in survivors. A number of in vitro and ex 
vivo assay systems have been established to better understand the infiltration and metastatic processes, to search for molecules 
that specifically block tumor cell infiltration and metastatic dissemination and to pre-clinically evaluate their efficaciousness. 
These systems allow analytical testing of tumor cell viability and motile and invasive capabilities in simplified and well-controlled 
environments. However, the urgent need for novel anti-metastatic therapies has provided an incentive for the further development 
of not only classical in vitro methods but also of novel, physiologically more relevant assay systems including organotypic brain 
slice culture. In this review, using publicly available peer-reviewed primary research and review articles, we provide an overview 
of a selection of in vitro and ex vivo techniques widely used to study growth and dissemination of primary metastatic brain tumors. 
Furthermore, we discuss how our steadily increasing knowledge of tumor biology and the tumor microenvironment could be 
integrated to improve current research methods for metastatic brain tumors. We believe that such rationally improved methods 
will ultimately increase our understanding of the biology of brain tumors and facilitate the development of more efficacious anti-
metastatic treatments.
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INTRODUCTION
Impressive achievements in genomic and epigenomic 
analyses of tumor tissues and individual tumor cells have 
revolutionized our understanding of primary brain tumors. 
Alterations detected on the genome or transcriptome 
level in large patient cohorts in combination with our 
increasing understanding of epigenetic gene regulation have 
disentangled apparently identical brain tumors as related 
but functionally different tumor entities.[1-5] Within such 
single tumor entities, alterations detected in their respective 
metastases suggested potential driver mechanisms of tumor 
progression.[6] This considerably more complex image we 
currently have is instrumental to better understand the highly 
heterogeneous nature of the tumor tissue itself and of the 
host environment interacting with it and shaping some of 
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its spatial, functional and morphological manifestations. 
However, in order to translate this still growing knowledge 
into clinical applications targeting the tumor phenotype, 
sophisticated model systems are necessary to explore and 
validate potential interference strategies under physiologically 
relevant conditions. In addition, functional genomics and 
cell-based molecular analyses are indispensable in many 
cases to clarify whether mutated or amplified genes are 
necessarily contributory to an altered proteome and causative 
for the cancerous phenotype. Moreover, the current wealth of 
genomic and transcriptomic data is insufficient on its own to 
isolate specific signaling networks driving tumor progression 
from a benign lesion to a disseminated cancer. Hence, to 
tackle the complexity of the metastatic process it is necessary 
to dissect it into individual steps that can be addressed with 
rationally adapted model systems. In this review we focus 
on in vitro and ex vivo primary brain tumor model systems 
and discuss how they can be improved and used to develop 
the molecular understanding necessary for designing novel 
anti-metastatic therapies. While none of these model systems 
on its own will suffice to tackle such a complex disease as 
cancer, they can effectively guide our search for efficacious 
and less toxic therapies and instruct the design of appropriate 
in vivo studies.
THE MACHINERY: ALTERED 
CYTOSKELETON DYNAMICS AND 
CELL MOTILITY DRIVE CANCER 
DISSEMINATION
Dissemination of tumor cells from the primary tumor 
causes healthy tissue infiltration and metastatic disease, and 
it hampers the efficacy of current cancer treatments. It is 
triggered by the transient or permanent induction of motility 
and invasiveness in the tumor cells. An essential prerequisite 
for primary brain tumor cell migration and invasion is the 
remodeling of the actin and tubulin cytoskeletons,[7-9] which 
not only provide force, traction and rigidity but also scaffold 
signaling complexes in a spatially controlled manner.[10-12] 
Hence, blocking motility and invasiveness by targeting 
pro-migratory cytoskeleton dynamics in tumor cells could 
prevent local tumor cell invasion, further dissemination 
from proximal metastases and the evolution towards a 
more aggressive phenotype. In a seminal review by Giese 
et al.,[13] the dichotomy of migration and proliferation in 
gliomas was recognized as the consequence of antagonistic 
cell regulation. Consequently, the authors concluded that 
an approach to influence the underlying mechanisms could 
be the basis of novel anti-invasive therapy strategies. A 
computational modeling study predicts that even a small 
increase in the motile capability of tumor cells, and the 
consequent short-range dissemination, increases net tumor 
growth and resistance to targeted therapy[14] [Figure 1]. 
Indeed, targeting tumor cell motility and invasiveness 
as a strategy against metastasis is an emerging theme in 
cancer research,[15-17] and the pro-migratory phenotype in 
tumor cells has been addressed in the past by a number of 
approaches that impair cell autonomous migration, cell-cell 
communication, cell-cell or cell-matrix interaction ([15] and 
references therein). This research led to the development 
of a number of clinical trial studies for solid tumors 
with approaches inhibiting various components of the 
aforementioned pro-migratory determinants.[15] 
Figure 1: Model of growth, progression and dissemination of primary brain tumors. The progression of primary brain tumors from a small neoplastic lesion to 
a metastasizing tumor through growth and dissemination of tumor cells is schematically visualized. The mode of tumor cell growth and dissemination varies 
between different tumors and involves random or guided, single or collective dissemination of tumor cells. The model depicting low range dissemination at 
early stages and the consequent increased net tumor growth is according Waclaw et al.[14]
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Despite of this, most current treatments including those 
against primary brain tumors still focus primarily on 
targeting growth and survival of the tumor cells. This lack 
of adequate anti-dissemination therapies is due in part to 
the complexity of the cell migration process itself and the 
redundancy of the signaling that controls its mechanics.
Additionally, tumor cells exploit mechanisms that normally 
direct physiological movements. However, the addiction 
of tumor cells to druggable pathways and our increasing 
understanding of cell mechanics and its control offer 
room for therapeutic interventions targeting tumor cell 
dissemination specifically.
The soil: the microenvironment in the brain
To address the impact of the tumor microenvironment 
on tumor growth and progression in vitro, we need (a) 
to better understand the intricate interaction between a 
growing neoplasm and its cellular, biophysical and chemical 
environment and (b) to continuously implement this 
increasing knowledge for advancing our model systems 
to mimic the micro environmental parameters better. The 
following paragraph will briefly discuss some relevant aspects 
of the still poorly understood interaction between the cells of 
primary brain tumors and their cellular host environment.
Biophysical properties of the brain 
microenvironment
Mammalian cells are sensitive to biophysical and chemical 
signals emanating from the surrounding matrix environment, 
the extracellular matrix (ECM), which can influence their 
behavior.[18-20] Depending on the tissue, composition and 
stiffness of the ECM differs markedly.[21] The stiffness or 
rigidity of a material such as a meshwork of collagen I fibers, 
describes its resistance to deformation. It depends on the 
elastic modulus (or compliance) of its constituting material 
e.g. fibrillar polymers of the protein collagen, which describes 
the ability to resist a distorting influence and to return to its 
original size and shape when the influence is removed. Thus, 
the stiffness of the ECM depends on its components and their 
elastic modulus. As the parenchyma of the brain is mostly 
devoid of fibers with a high elastic modulus such as collagen 
or fibronectin fibrils, its stiffness is very low compared to 
the ECMs in other tissues of the human body.[22] Conversely, 
the leptomeniges in the subarachnoid space, to where 
metastatic medulloblastoma tumors preferentially spread,[22] 
are connected by a network of collagen-rich trabeculae,[23,24] 
which likely is much stiffer than the parenchyma.
The basic constituents of the brain ECM are 
glycosaminoglycans with their most prominent member 
hyaluronan (Hyaluronic acid, HA), link proteins, lecticans 
and tenascins.[25] HA acts as a backbone for the assembly of 
a relatively loose and flexible meshwork. The distribution 
and composition of these ECM components in the 
developing rodent brain is changing during embryonal and 
postnatal phases and reaches a mature stage at postnatal 
day 20.[25] However, disease-associated remodeling of the 
CNS ECM has been observed after injury,[25-28] suggesting 
that growing primary neoplasms in the brain may also 
alter the surrounding ECM. Relatively little change in 
the expression levels of a small set of proteins in normal 
brain tissue and in brain tissue surrounding invasive 
glioblastoma was observed in a recent study,[29] except for 
Tenascin-R and CD168, which were both up-regulated. 
Matrix stiffness regulates proliferation and motility of 
Glioblastoma multiforme (GBM) cells[30] and the increase 
of ECM stiffness through fiber crosslinking by the product 
of the LOX gene causes their enhanced integrin-dependent 
invasion.[31] The specific impact of matrix stiffness on 
cell migration was investigated in glioma and found to 
decrease motility in agarose-stiffened collagen gels[19] 
and to increase motility in matrigel.[32] This somewhat 
conflicting result may be explained by the receptors sensing 
the matrix environment and their underlying signaling, 
which markedly influence the migratory outcome. Hence, 
the impact of matrix stiffness on the migratory behavior 
should always be investigated in the context of the cognate 
receptors. Whether matrix stiffness could exert a selective 
pressure on brain tumor cells contributing to the altered 
genetic landscapes is still poorly understood. One potential 
sensor and transducer of matrix stiffness in brain tumors 
is the HA receptor CD44, which was identified in GBM to 
facilitate invasiveness in stiff matrices.[33] 
Chemical properties of the brain 
microenvironment
Analogous to solid tumors outside the CNS, where parallels 
between the inflammatory response in wounds and the host 
tissue response to growing neoplasms has been noted,[34] 
remarkable similarities in brain tissue response after injury 
and in the vicinity of brain tumors exist.[35] Tissue response 
is driven initially by a local repertoire of innate and adaptive 
immune cells that is subsequently supported by infiltrating 
cells of the adaptive immune system. In the brain, an 
immune privileged site of the human body, tissue response is 
driven by microglia/macrophages and astrocytes. Microglia 
are involved in first-line innate immunity in response to 
brain injury, when they convert to an active proliferating, 
migrating and phagocytic phenotype.[36] Microglia and 
macrophages accumulate in and around glioma to which 
they are suspected to be attracted by glioma-secreted chemo 
attractants such as monocyte chemotactic protein-3 (MCP-
3), colony-stimulating factor 1 (CSF-1), granulocyte-
colony stimulatory factor (G-CSF), and hepatocyte growth 
factor/scatter factor.[37] Besides direct stimulatory functions 
through secretion of growth factors or proteolytic enzymes, 
glioma infiltrating macrophages were also found to 
contribute to tumor vascularization and net tumor growth.[38] 
Surprisingly, however, malignancy or primary cranial 
origin did not seem to determine immune cell infiltration 
as no significant difference in immune cell distribution 
was observed between different primary or secondary 
brain malignancies (Glioma, PNET/Medulloblastoma, 
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adenocarcinoma, melanoma meningioma).[39] A more 
recent study correlating inflammatory gene expression 
with the molecular subgroup of medulloblastoma, revealed 
significantly increased immune cell infiltration of tumor 
associated macrophages and other immune cells in the SHH 
subgroup,[40] suggesting a potential therapeutic relevance of 
immune cell targeting specifically for this subgroup.
Microglia are outnumbered by astrocytes, which account 
for nearly half of all cells resident in the brain. Astrocytes 
respond to brain injury and tumor growth in a process 
named reactive gliosis. On the one hand, reactive gliosis 
and the associated secretion of growth factors and cytokines 
help repairing injury in the CNS.[41] On the other hand, 
the astrocytic response in the tumor microenvironment 
also contributes to disease progression. Of note in this 
context is the capability of U87MG glioblastoma cells 
to induce astrocyte activation through the secretion of 
Receptor Activator of NF-kB ligand (RANKL), which 
in turn facilitates glioblastoma invasiveness in vivo by 
releasing FGF4, FGF6, TGF-β and Hepatocyte growth 
factor.[42] Consistently, co-cultured astrocytes display 
increased expression levels of a number of growth factors 
and cytokines and enhance invasiveness of glioblastoma 
stem-like cells.[43] Another decisive input could stem 
from astrocytes activated by the neoplastic lesion and the 
consequent up-regulation of matricellular proteins such 
as secreted protein acidic and rich in cys-teins (SPARC) 
in astrocytoma[44] and medulloblastoma[45] or connective 
tissue growth factor in glioma,[46] which jointly with 
additional matricellular proteins remodel neuronal tissue 
during development or after brain injury.[28] Significantly, 
the concept of reciprocal stimulation of tumor cells and 
astrocytes was recently also identified in metastatic 
melanoma, which elicits an inflammatory cytokine response 
in astrocytes that facilitates brain metastasis.[47] 
Combined, these studies emphasize the importance of 
incorporating environmental parameters into experimental 
protocols to explore their contribution to the proteomic 
landscape and the functional outcomes of primary brain tumors.
CURRENT IN VITRO MODEL SYSTEMS TO 
ADDRESS FUNCTIONS OF METASTATIC 
PRIMARY BRAIN TUMORS
Preclinical evaluation of novel anti-metastatic therapy 
strategies in animal models will remain an essential step 
towards the development of novel therapeutics. However, 
cell culture models are instrumental for deciphering 
essential morphological and functional aspects of the 
biology that drives neoplastic lesions into disseminated 
diseases. They also provide essential insights for designing 
appropriate animal models and help elucidating the causes 
that may underlie controversial outcomes of in vivo studies. 
Although a general trend towards 3D model systems 
can be noted, a majority of experiments in tumor-related 
research are still conducted in 2D settings. For a general, in 
depth description and comparison of 2D versus 3D culture 
systems, the reader is referred to Zimmermann et al.[48] who 
emphasized the need of higher throughput approaches to 
understand cell dissemination capabilities on one hand and 
the role of the microenvironment on the other hand.
The “ideal” in vitro cell culture model should mimic one or 
several of the following characteristics of the in vivo tumor: 
proliferative capabilities and morphology of the tumor cells, 
cellular and phenotypic heterogeneity, a dynamic tumor 
microenvironment and the drug response profile. A series of 
excellent reviews have recently described in depth the use 
of 3D tissue culture model systems in pathophysiology[49] 
and high-throughput drug candidate toxicity analysis,[50] 
to identify tumor-specific signaling pathways and 
biomarkers,[51] and to determine growth determinants for 
drug target discovery.[52] These reviews delineate what 
parameters contribute to a disease representing, efficient 
Figure 2: Tumor cell growth, survival and dissemination are governed by extrinsic and intrinsic parameters. Tumor cells are under the spheres of influence 
of intrinsic and extrinsic parameters. Colored ovals represent various degrees and manifestation patterns of such parameters, which dramatically increase in 
number and complexity in the organotypic environment
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Table 1: Studies using 3D primary brain tumor model systems
Cells Tumor type Condition Experiment Matrix or scaffold Effect Ref.
U87MG
Glioblastoma 
multiforme 
(GBM)
2D, 3D 
neurospheres
Analysis of 
cell growth in 
neurospheres, 
wound healing 
after DDX6 or 
PHLDB1 knock-
down
None
50 % reduction in 
neurosphere formation 
and migration
[83]
U-251MG, 
U-343MG, 
LN-229
Glioma 2D, 3D spheroid culture
Analysis of stable 
over-expression 
of wt and 
mutant proteins 
under different 
oxygenation.
None
Mutant IDH1 causes 
reduced cell migration 
and differences in 
growth properties in 
3D spheroid cultures.
[84]
U87 GBM 2D, 3D single cell embedding
Spheroid in soft 
agar, 2D culture, 
analysis of Glioma 
co-culture with 
MSCs expressing 
suicide gene. 
Soft agar
Stem cell-mediated 
anti-tumor effect. 
Increased IC50 under 
3D culture conditions.
[85]
KNS42, U87, 
Res196, 
T7/11, GB-1
Pediatric and 
adult GBM and 
ependymoma, 
pediatric mixed 
glial tumor
3D, long-
term culture of 
large cellular 
aggregates
Rotary cell culture 
to generate large 
cell aggregates, 
growth on top of 
matrigel.
None
Angiogenic change 
and endothelial marker 
expression in GBM 
aggregates
[86]
SHSY5Y, 
T98G, 
U138MG
GBM and 
neuroblastoma
3D, spheroid 
culture
Exposure to 
Doxorubicin, 
Etoposide and 
Vincristine, 
analysis by 
electrochemical 
impedance 
spectroscopy.
None
Cytotoxic effect 
measured in 2D 
cannot be extrapolated 
to 3D. 3D cultures 
can also display 
higher sensitivity to 
chemotherapeutics.
[58]
U67-MG GBM 2D
2D wound healing, 
tubulogenesis 
assay on matrigel 
after exposure 
to rapamycin or 
hypoxia.
None Tube structure formation [87]
Rat C6, 
NSCs adult 
hippocampal
Glioma 3D, spheroid culture
Comparison of 
different 3D tissue 
clearing protocols.
None
Validation of tissue 
clearing protocols 
of high resolution 
imaging of spheroid 
culture.
[88]
U251 Glioma
2D and 3D 
rotary cell 
culture system 
Proteomic 
comparison of 2D 
and 3D cell culture.
None
Increased HLA-E 
expression in 3D 
culture and increased 
resistance to NK-
mediated cytotoxicity. 
[89]
DBTRG, T98, 
U87, A172, 
8MGBA, 
42MGBA, 
DKMG, 
GAMG, 
GMS10, GSCs
GBM 2D, 3D, single cell embedding 
Cytotoxicity assays 
using collagen 
I and collagen 
I-HA matrices in 
combination with 
receptor tyrosine 
kinase inhibitors.
Bovine 
skin 
collagen I, 
Collagen 
I-HA 
mixtures
Collagen-based 
3D matrix reduces 
sensitivity of GSCs 
to receptor tyrosine 
kinase inhibitors.
[60]
                                                                             Contind...
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Cells Tumor type Condition Experiment Matrix or scaffold Effect Ref.
U87-MG, 
primary MB 
samples
GBM 2D, 3D culture
Comparison of 2D and 
3D cultures for growth 
and viability after 
irradiation or treatment 
with TMZ, cisplatin or 
carmustin. 
ExtracelTM 
(Polyethylene-
based hydrogel 
with HA and 
gelatin).
3D cell culture is 
better morphological 
correlate to in vivo 
tumor, 3D grown 
GBM moderately less 
sensitive to irradiation.
[90]
U118-MG GBM
3D culture, cells 
grown on rigid 
matrix 
Evaluation of 
growth and stem cell 
properties
Porous chitosan-
HA
Porous chitosan-HA 
increases growth and 
causes up-regulation of 
stem-cell markers
[63]
Patient-
derived tumor 
material
GBM 3D, single cells
Embedding 
in hydrogels, 
morphology and cell 
migration analysis, 
single cell tracking for 
motility. 
Hydrogels made 
of collagen I, III, 
or collagen-HA 
mixtures
HA causes rounded 
morphology and 
reduces motility of 
matrix-embedded cells. 
[62]
U87-MG, 
U87+EGFR Glioma 3D, single cells
Analysis of growth, 
metabolic activity 
and HIF-1 VEGF, 
MMP-2, MMP-
9 and Fibronectin 
production.
GelMA or 
PEG4A hydrogels 
supplemented 
with 
methacrylated 
HA (HAMA) 
at increasing 
concentrations
Increasing HAMA 
concentrations cause 
up-regulation of 
fibronectin, VEGF and 
HIF-1.
[64]
A-172 Glioma
3D, single cells, 
microfluidic 
chip 
Analysis of single cell 
viability, F-actin size 
and cellular orientation 
in embedded cells 
under flow and VEGF 
in microfluidic chip.
Acrylated HA 
cross-linked with 
MMP-sensitive or 
RGD peptides
F-actin reorganization 
and re-orientation of 
cells in response to 
flow and VEGF.
[91]
OSU-2 GBM 3D, single cells 
Evaluation of matrix 
stiffness impact on 
tumor cell morphology 
and migratory/invasive 
capabilities.
Matrigel with 
varying stiffness
Increased matrix 
stiffness causes 
increased invasive 
motility.
[32]
M059K, 
HepG2, 
CYP3A
GBM, 
Hepatoblastoma
3D, micro-
scale perfusion 
system
Evaluation of liver 
cell metabolism on 
cytotoxic effect of IFO 
and TMZ.
Polylactic acid 
scaffold
TMZ showed much 
lower cytotoxicity 
against GBM cells in 
3D than in 2D. IFO 
effect dependent on 
metabolic activity of 
cytochrome P450 in 
hepatocytes.
[68]
U251MG, 
LN229 and 
U87MG
GBM 3D, organotypic slice culture
Evaluation of Rho-
family GTPase 
activation during 
GBM invasion in 
brain slice and 3D 
matrigel culture. Use 
of Rho-family GTPase 
fluorescent protein 
sensors.
Matrigel, slice 
culture
Perivascular and 
intraparenchymal 
invasion is associated 
with increased Rac and 
Cdc42 and reduce Rho 
GTPase activity.
[53]
U87, U251HF, 
SNB19, 
LNZ308, 
LN229
Glioma 2D, 3D 
Comparison of protein 
expression in cells 
grown under 2D or 
3D conditions and in 
different oxygenation.
AlgiMatrix
Differential expression 
of invasion, survival 
and hypoxia driver 
proteins between 2D 
and 3D. Effect of 3D 
growth dominates 
oxygenation.
[92]
                                                                                                                                                          Contind...
            Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ May 18, 2016 ¦ 155
Cells Tumor type Condition Experiment Matrix or scaffold Effect Ref.
LN18, GL15, 
U87, A172 GBM 2D, 3D
Seeding of GBM cells on 
brain Hi-spots and exposure 
to anti-proliferative drugs 
Ara-C, Taxol and TMZ
Brain Hi-Spots
Increased anti-
proliferative effect of 
TMZ on GBM cells 
maintained on Hi-spots.
[65]
C6 rat, U-87 
MG, U-118 MG Glioma
2D, 3D, 
Matrigel and 
chitosan-
alginate 
scaffolds 
Comparison of growth 
and morphology and 
secretion of VEGF, MMP2, 
fibronectin and Laminin 
between cells grown in 2D, 
in matrigel or on chitosan-
alginate scaffolds.
Matrigel, 
Chitosan-
alginate 
scaffolds 
Growth on chitosan-
alginate scaffolds 
reduces growth but 
increases secretion 
of VEGF, MMP2, 
fibronectin and 
Laminin.
[93]
LN18, F98, 
F98EGFR- vIII, 
C6 rat, U-87 
MG,
Glioma
2D, 3D 
spheroid 
culture, 
transwell 
migration
Evaluation of SHA impact 
on cell growth, collagen 
I invasion and mRNA 
expression of genes relevant 
for cell-cell and cell-matrix 
interaction.
Collagen I
SAHA treatment causes 
reduction of invasion 
and the reorganization 
of the matrix 
surrounding the tumor 
spheroids.
[94]
U178, U251 Glioma 3D transwell 
Analysis of transwell 
invasion and migration after 
compound inhibition of 
PKC∂.
Collagen I 
supplemented 
with Tenascin C
Tenascin-C deposition 
triggers glioma invasion 
in a PKC∂-dependent 
manner.
[95]
U373 Glioma 3D spheroid
Analysis of growth 
and dissemination in 
increasingly stiff collagen I 
gels.
Collagen 
I-agarose
Matrix stiffness 
impacts on glioma 
cell invasiveness. 
High stiffness blocks 
invasiveness.
[19]
U251, U178 Glioma 3D, single cells 
Quantification of transwell 
migration of cells stimulated 
with TNF-α, IL-1 or a 
combination of both.
Collagen I
Interleukin-1 beta (IL-
1b) and tumor necrosis 
factor-alpha (TNF-α) 
increase glioma cell 
invasiveness in 3D 
with parallel increased 
MMP-2 and MMP-9.
[96]
Primary mouse 
G3 MB Medulloblastoma
3D 
neurospheres 
Neurosphere compound 
toxicity assays using FDA-
approved drugs and ATP-
sensor dye. 
None
FDA-approved 
Pemetrexed and 
Gemcitabine 
significantly block 
proliferation of G3 MB.
[55]
DAOY, UW228 Medulloblastoma
2D, 3D 
transwell, 3D 
micro beads
Quantification of 
collagen invasion after 
HGF stimulation, small 
compound kinase inhibitor 
or siRNA treatment in cells 
seeded on Micro-beads and 
embedded in collagen I 
matrix. 
Collagen I
HGF-induced c-Met 
activation promotes MB 
cell invasion through 
the kinase MAP4K4.
[9]
DAOY, 
UW228, Med 
PDX1712, 
MedPDX411, 
primary MB
Medulloblastoma
2D, 3D micro 
beads and 
spheroids
Quantification of collagen 
invasion and cell migration 
after growth factor 
stimulation using invasion 
counter platform for 
automated quantification 
of motile cell behavior in 
different environments. 
Collagen I
HGF, EGF and bFGF 
are strong promoters of 
MB cell migration and 
invasion
[56]
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model system: the system should mimic biophysical and 
chemical properties of the tissue environment (composition 
and stiffness of matrix, availability of growth factors, 
cytokines, metabolites) in a well controllable manner, 
the cells should be observable to increase output options 
(morphological analysis, use of fluorescent protein[53]and dye 
Cells Tumor type Condition Experiment Matrix or scaffold Effect Ref.
DAOY, UW228 Medulloblastoma 3D, transwell migration
Quantification of 
VEGE-A induced, 
PERK-dependent 
transwell migration.
Matrigel
Tumor cell-derived 
VEGF-A promotes 
medulloblastoma cell 
migration and invasion 
through VEGFR2 and 
enhanced by PERK.
[97]
DAOY, UW228 Medulloblastoma 3D, transwell migration
Quantification of 
EphB1 effect on SHH 
medulloblastoma 
transwell migration 
using electrical 
impedance 
measurements.
None
Knockdown of Eph-B1 
causes reduction in B-1 
integrin expression and in 
growth and migration.
[98]
DAOY Medulloblastoma
3D, µLane 
microfluidics 
system
Quantitative and 
qualitative analysis of 
chemotactic response 
of MB cells to a 
gradient of EGF in a 
microfluidic system.
Matrigel
Matrigel invasion of MB 
cells towards an EGF 
gradient is blocked by 
pharmacological PI3-K 
inhibition.
[99]
DAOY Medulloblastoma
3D, transwell 
migration, 
xCelligence 
assay
Quantitative analysis 
of PDGFR control 
of CXCR4 pro-
migratory signaling 
in SHH MB model.
Matrigel
PDGF signaling restricts 
expression of negative 
regulator GRK6 and 
promotes CXCR4-Src-
dependent cell migration. 
[100]
DAOY, UW228-
3 Medulloblastoma
3D confrontation 
co-culture
Quantification of 
repulsive action of 
Slit-Robo signaling 
during MB invasion.
Collagen I Slit represses MB invasion in collagen gels. [101]
DAOY Medulloblastoma 2D/3D transwell migration
Evaluation of impact 
of matricellular 
SPAR on MB cell 
migration and 
invasion
Matrigel
SPARC suppresses 
migration and invasion 
by repressing Rho-
GTPase activation 
and by triggering Src-
dependent cytoskeleton 
reorganization.
[45]
DAOY, D283 Medulloblastoma
2D spheroid 
outgrowth, 
3D transwell 
migration
Comparison of 
invasion and self-
renewal. Analysis 
of higher versus 
lower self-renewing 
tumor spheres and 
stationary versus 
migrating adherent 
MB cells with respect 
to CD271 and CD133 
expression.
Collagen I
Highly self-renewing 
CD271 high, CD133 
low MB cell population 
in the core sustains 
tumorigenesis. 
Commitment to 
migration/invasion 
(metastatic phenotype) 
is identified by reduced 
CD271 and increased 
CD133 signature.
[102]
Overview of a selection of primary brain tumor studies that used 3D cell culture technologies. Ara-C: cytosine β-D-arabinofuranoside; 
CXCR4: CXC-motif-chemokine receptor 4; PERK: pancreatic endoplasmic reticulum kinase; EGF: epidermal growth factor; GBM: 
glioblastoma multiforme; GM-CSF: granulocyte-macrophage colony stimulating factor; GSCs: glioblastoma stem cells; GRK6: 
g-protein coupled receptor kinase 6; HA: hyaluronic acid; HAMA: methacrylated HA; HGF: hepatocyte growth factor; IDH1: isocitrate 
dehydrogenase 1; IFO: ifosfamide; MB: medulloblastoma; MMP: matrix metalloproteinase; PEG: polyethylene glycol; PDGFR: 
platelet-derived growth factor receptor; PI3-K: phosphoinositide 3’Kinase; RGD: l-arginine, glycine, and L-aspartic acid; SAHA: 
suberoylanilide hydroxamic acid (or vorinostat a HDACi); SPARC: secreted protein acidic and rich in cysteine; Src: rous sarcoma 
kinase; TMZ: temozolomide; VEGF: vasculature endothelial growth factor; 2D/3D: two dimensional/three dimensional
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sensors[54]) and it should have a high-throughput potential.
To understand the causes and consequences during 
pathophysiological progression from a primary neoplastic 
lesion in the brain towards a metastatic cancer and to pre-
clinically test potential intervention strategies, we thus 
require model systems that mimic not only the proteomic 
heterogeneity of the tumor cell itself but also the reciprocal 
interactions between the tumor and the receiving brain 
tissue [Figure 2]. The following paragraph provides an 
overview over some recent approaches in primary brain 
tumor research. It highlights the difficulty to design an 
optimal, tumor-adapted system and emphasizes the need to 
further improve currently used systems.
2D and 3D model systems in primary brain 
tumor research
A number of articles have been published in the last few years 
that used in vitro model systems to evaluate effects of novel 
potential treatment strategies on growth, viability or motile 
behavior of primary brain tumors [Table 1]. A general consensus 
has been reached in that 3D cell culture model systems reflect 
the specifics of the in vivo situation better compared to 2D 
model systems. On the down side of this was the lack of 
high-throughput capability of 3D methods that hampered 
until a few years ago their broader use in combination with 
in screening approaches. A milestone in this context was the 
generation of spheroid cultures in 96 or even 384 well format 
from primary brain tumors that allowed the parallel testing or 
large sample sizes.[54-56] In these studies, diagnostic dyes and 
fluorescent proteins were used individually or in combination 
for probing cellular functions on the one hand and for 
discriminating specific cell populations on the other hand. A 
general protocol describing the reproducible establishment 
and microscopy-based analysis of spheroid cultures using 
fluorescent protein quantification in high throughput was 
described recently.[57] As an alternative to fluorometric read-
outs, electrochemical impedance spectroscopy was used to 
quantify different susceptibilities of 2D versus 3D spheroid 
culture of glioblastoma and neuroblastoma cell lines to 
cytotoxic compounds[58] and to determine the therapeutic 
window of these compounds. Using different combination of 
dyes to separate subpopulation of cells grown in co-culture 
combined with diagnostic flow cytometry and two-photon 
microscopy allowed to further refine the selective output of 
3D methods.[54] However, high-throughput capabilities and 
accuracy of a selected read-out has to be carefully balanced 
and discriminating phenotypic differences at single cell 
level in 3D cultures in high throughput remains a formidable 
challenge.
The impact of the embedding matrix on the 
behavior of the tumor cell
The choice of the embedding matrix is of outmost 
importance for 3D cultures, in particularly for primary brain 
tumors that encounter in vivo mostly brain parenchyma and 
collagen-rich surfaces and structures in the subarachnoid 
space.[23,24,59] Hence, the biophysical and chemical properties 
of the matrix should be adjusted to those in the location of 
growth and metastatic dissemination of the tumor under 
investigation. In this context, Fernandez-Fuente et al.[60] 
investigated the impact of different environmental conditions 
on glioblastoma stem cells (GSCs). They found that GSCs 
grown in collagen-based 3D conditions were markedly less 
susceptible to receptor tyrosine kinase inhibition by currently 
available inhibitors, suggesting that oncogene addiction of 
tumor cells could also be bypassed by adhesion signaling.[61] 
Interestingly, matrix stiffness or the addition of hyaluronic 
acid (HA) did not affect the sensitivity of the GSCs in this 
study. Primary cells from glioma patient tumor material 
exposed to increasing concentrations of HA responded with 
rounded morphology and reduced migration, suggesting 
that HA concentrations may affect glioma cell behavior.[62] 
Consistently, addition of HA to porous chitosan scaffolds[63] or 
to artificial hydrogels[64] increased the expression of stem cell 
markers and VEGF and HIF-1, respectively. However, the 
finding that increasing matrix stiffness - by adding agarose to 
a collagen I matrix - blocks glioma invasiveness,[19] suggested 
that stiffness alone and independent of ligand binding acted 
as a critical determinant for primary brain tumor cell function. 
An improved in vitro environment for brain tumor research 
would consist of neuronal and brain-resident interstitial 
cells that secrete the brain-specific ECM components into 
which the brain tumor cells can then be implanted. Such 
an environment was established from brain tissue extracts 
on micro filters (Hi-spots) on which GBM cell sensitivity 
to anti-proliferative compounds was tested.[65] Despite its 
high-throughput potential, a setback of this method is the 
lack of control over the cellular composition in the Hi-spots 
and the absence of brain-specific architectural organization. 
A while ago, a simple but intriguing co-culture model of 
medulloblastoma and leptomeningeal cells was published, 
and it indicated paracrine, growth-promoting effects of 
latter that might be instrumental for studying the notoriously 
difficult to grow primary tumor cells in vitro.[66] The ideal 
“organotypic environment” for primary brain tumor research 
was already in development in the early seventies of the last 
century, when the organotypic brain slice culture (OBSC) 
technology was established.[67] The advantages of OBSCs are 
that micro environmental parameters and a relatively correct 
architectural organization are maintained that mimic the in 
vivo situation (see below).
Increasing complexity: system impact and single 
cell behavior
Neither are tumor functions disconnected from other tissues 
and the organs nor can the impact of tissues or organs on drug 
efficacy in the targeted tumor be predicted. An interesting 
approach to evaluate the effect of metabolic activity on 
cytotoxicity of compounds and chemotherapeutics in vitro 
was tested by Ma and colleagues using a 3D micro-tissue 
perfusion system.[68] TMZ and IFO were perfused through 
hepatocytes before exposure to GBM cells and a clear 
impact of hepatocyte-provided cytochrome P450 on IFO 
activation could be shown. Analogous experimental follow-
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ups are a number of organ on a chip technologies that are 
currently developed for assaying different disease states[69] 
and testing drug effects and metabolization.[70] 
On the opposite side of the spectrum is the need to resolve 
the mechanisms underlying brain infiltration of single 
tumor cells, which necessitates approaches allowing the 
quantitative analysis of molecular events in individual 
cells. This problem was tackled for the activation status of 
the important Rho family GTPase’s - Rho, Rac and Cdc42 
- in glioma cells.[53] Hirata et al.[53] used Rho-GTPase-
FRET (Förster energy resonance transfer) probes, where 
spatial activation of the GTPase’s was monitored by a 
shift in fluorescence signal. Rho-family GTPase-FRET 
fusion protein-expressing glioma cells were orthotopically 
implanted in rat brains and later analyzed inside brain 
slice cultures derived of these brains using two-photo 
microscopy. This study revealed higher Rac1 and Cdc42 and 
lower RhoA activities in glioblastoma cells penetrating the 
brain parenchyma than those advancing in the perivascular 
regions, and suggested that different driver mechanisms 
could exist for single cell dispersion in glioma. 
Together, these studies highlight the need for adapting the 
model system to the specifics of the biological context, 
with the consequent inclusion of biophysical or chemical 
components that best reflect the in vivo situation. Besides 
high-throughput screening platforms for the identification of 
novel pro-metastatic key players or alternative interference 
strategies against metastatic dissemination, we also need 
improved phenotype-based single cell analysis to decipher 
clonal differences and micro environmental impact on 
tumor behavior at the single cell level.
Organotypic brain slice culture (OBSC) in 
primary brain tumor research
A number of causal gene(s) and associated genetic mutations, 
molecular changes, probable targets and treatments for 
a variety of primary brain tumors have been identified. 
Despite of this, the process of dissemination, metastasis of 
the tumor cells from the primary site, and tumor recurrence, 
which is the leading cause for brain tumor related mortality 
in patients, remain obscure. Total removal of the primary 
tumor is on many occasions impossible at the microscopic 
level due to the insidious infiltration of the tumor cells 
into the surrounding brain tissue.[71] This majorly results in 
therapeutic failure and urges for model systems that allow 
addressing brain tumor cell invasion specifically. Standard 
3D in vitro invasion assays use ECM macromolecules that 
mimic the basement membrane (e.g. matrigel) as barriers to 
tumor invasion. These assays (described above and in table 
1) although quick, reliable, commercially available and easy 
to perform, have several limitations. They do not take into 
account the unique ECM composition in the brain and thus 
provide artificial environments that fail to closely mimic 
the normal brain tissue/tumor environment. This is further 
emphasized by the fact that distinct types of brain tumors 
localize within specific regions of the brain, highlighting 
the need for different microenvironments for modeling 
tumor growth and invasiveness. To circumvent this, mouse 
models have been generated for studying tumor propagation 
via orthotopic or subcutaneous xenografting of tumor cells. 
These experiments, however, are ethically controversial if 
inappropriately conducted, costly, labor intensive and need 
lengthy time periods for animal surgery and subsequent 
tumor development (especially for low grade tumors). These 
challenges and limitations highlight the need for developing 
a novel system wherein living brain tissue can be used as an 
ideal matrix for studying tumor cell growth and invasion.[72] 
One such system is the organotypic culture, where cellular 
constituents of organs or parts of organs are allowed to 
regrow into or persist as organ replacements. 
An excellent overview of 3D organotypic cultures has 
recently been provided,[73] which describes their potentials 
as experimental systems to visualize cellular mechanisms 
that drive tissue development, to study the genetic 
regulation of cell behaviors in tissues and to evaluate the 
role of micro environmental factors in normal development 
and disease. One hallmark of organotypic cultures is the 
tissue environment mimicking the structural and functional 
specifics of the organ of origin. This turns them into 
attractive models for cancer research to explore tumor host 
tissue interactions and to advance therapeutic approaches. 
Organotypic brain slice culture for visualization 
and quantification of brain tumor cell 
dissemination
OBSCs allow culture, maintenance and long-term survival 
of sections from any tissue of the CNS. Slices are mostly 
cultured at an air/liquid interface by either continuous 
rotation using the roller tube method or on a semi porous 
membrane using the Stoppini method.[74] Brain tissue slice 
cultures maintain their normal cytoarchitecture, complex 
cell relationships and biochemical and electrophysiological 
properties. OBSCs have been widely used in the field of 
neurobiology for synaptogenesis, neurogenesis, myelin 
formation, as models for studying neurodegeneration, for 
neuroprotective and neurotoxic assays, etc.[67] In the field of 
brain tumor research, they are an ideal platform to access the 
tumor microenvironment under intact anatomical conditions. 
Indeed, Jung et al.[71] established a brain tumor slice model 
wherein they used human white matter specimens in the 
upper chambers of transwell culture dishes. After 24 h, 
control human astrocytoma cells stably expressing enhanced 
GFP or GFP-RHAMM (receptor for hyaluronan-mediated 
motility) transfected astrocytoma cells were placed in a 
small centrally punched-out hole in the slice. The infiltration 
and migratory behavior of the GFP-expressing astrocytoma 
cells could be easily studied using confocal laser scanning 
microscopy (CF-LSM) up to 30 days post implantation. The 
authors were able to demonstrate that different astrocytoma 
cell lines display different degrees of invasion and that 
the migration of the human astrocytoma cells could be 
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stimulated or, using antisense targeting strategies, specifically 
blocked.[71] In an analogous study it was demonstrated that 
(1) the invasive behavior of the astrocytoma cells in the brain 
slice co-culture is not always identical to the results obtained 
from 2D migration studies, (2) the tumor cells spread out 
multidirectionally, (3) frozen human normal brain tissue 
can be used for the organotypic culture, (4) there were no 
obvious signs of necrosis, and (5) the brain cytoarchitecture 
and viability was preserved for at least 14 days.[72]
Although the human origin of the biopsies used as the host 
tissue in these studies excludes species-specific effects in 
the co-culture, slices from newborn rat or mouse brains are 
excellent alternatives. They offer several advantages: brain 
regions corresponding to the in vivo tumor localization can be 
chosen, developmental stage of the brain slice can be adjusted, 
multiple replicas from same brain region can be generated, 
and the use of transgenic animals allows modification of 
the cellular microenvironment. Ohnishi et al.[75] established 
OBSCs from 2-day-old neonatal rat brains, which were 
transferred on double-layered membranes consisting of two 
different membrane types and maintained at an interface 
between the air and the culture medium. The slices were 
then co-cultured with C6 glioma cells labeled with PKH2 
fluorescent dye. After 2 days of co-culture, the exogenous 
application of the chemotactic stimulator neural cell adhesion 
molecule L1 triggered tumor cell migration from the upper to 
the bottom membrane through the brain slice.[75] Since this 
study lacked CF-LSM analysis, OBSCs were subsequently 
performed by the slightly modified Stoppini method, which 
allowed quantifying glioma cell invasion using confocal 
microscopy.[76] This study revealed that the migrating cells 
showed a strong increase in immunoreactivity for matrix 
metalloproteinase 2 and 9.[76] Analogous OBSC technology 
was later used for mouse brain slices to quantify the 
invasiveness of glioma[77] and to correlate it with histological 
type.[78] Both studies used human, DiI-stained glioma biopsy 
tumor fragments and GFP-expressing spheroids directly 
implanted in the cortex of brain slices derived from 7 day 
old mice. This intraslice implantation system could be 
maintained in culture for 2 to 4 weeks. Quantification of 
the distance and density of the tumor cell invasion revealed 
that GBMs were 2-4 times more invasive than the lower 
grade glioma cells (LGGs). Within the different groups 
and grades of GBMs and LGGs, heterogeneity in terms of 
invasion was seen. It was also observed that the spheroids 
were less invasive in comparison to the directly grafted 
fragments. Overall using this system, Palfi et al.[77,78] and de 
Bouard et al.[77] could successfully recapitulate, monitor and 
quantify the invasion of single cells and the dissemination 
of glioma ex vivo. Recently, Chadwick et al.[79] developed 
OBSCs from postnatal day 6 mice and cultured the whole 
brain slices on membrane inserts coated with laminin. Tumor 
cells (astrocytoma and medulloblastoma) were stained with 
Cm-DiI for monitoring, and dispensed on the center of the 
slice. This co-culture system remained viable for one week 
and effects of drug therapies on tumor cell proliferation, cell 
death or changes in protein expression were successfully 
analyzed. Thus, Chadwick et al.[79] used the OBSC system 
as a qualitative and quantitative assay to calculate the fold 
change in the number of cells during the period of slice 
culture. Furthermore, they investigated either the whole brain 
or specific regions within the brain, to assess environmental 
impact on primary brain tumor cell growth.
Organotypic brain slice culture to study the 
micro environmental impact
Malignant astrocytoma/GBM cause mortality by local tumor 
growth and brain invasion rather than systemic metastasis. 
GBM tumor cells diffusely infiltrate the brain parenchyma 
within and along the white matter tracts or around cerebral 
blood vessels,[53] and rarely penetrate basal lamina structures 
at the glial limitans externa. Analogously, malignant 
medulloblastoma must also infiltrate cerebellar tissue for 
distal dissemination. Moreover, resection of MB tumors is 
inevitably followed by relapse if the patients are not treated 
with cranio-spinal radiotherapy and chemotherapy, suggesting 
the occurrence of local dissemination of tumor cells from the 
primary medulloblastoma. In vitro studies aiming at better 
understanding the local invasion process have been hampered 
by the lack of identification of the brain ECM macromolecules 
involved and the only poorly understood implication of the 
cellular microenvironment. In vivo approaches on the other 
hand, offer too little spatial and temporal resolution to 
monitor tumor-microenvironment interactions appropriately. 
Thus, OBSCs could provide an important platform to study 
the cross-talk between the tumor cells and normal cells in 
a physiologically relevant environment. OBSCs can be 
used for investigating the microenvironment and its impact 
on the growth and spread of primary brain tumors, and for 
testing the measures that could be taken to prevent or treat it 
effectively.[79] Although, there is a lack of vascular supply to 
the tissue in the slices, capillaries do survive in these sections 
without any circulation.[80] Despite of the fact that there is 
no blood flow and that the capillaries are not functional, it is 
likely that they are still capable of expressing and secreting 
various molecules,[81] which could affect other cell types in 
the slice culture including the tumor cells. In addition, the 
intriguing exchange between tumor cells and astrocytes and 
the suspected tumor promoting functions of astrocytes [41-43] 
urges for novel studies addressing the therapeutic potential of 
the astrocyte-tumor interaction, for which organotypic slice 
culture would be an ideal system.
Along with their use for monitoring tumor dissemination, 
OBSCs have also been used for high resolution imaging 
of cytoskeletal structures in living glioblastoma cells. For 
this, glioblastoma cells were transfected with GFP-actin and 
placed onto murine brain slices and spinal cord explants. 
Using live-cell imaging to visualize the cytoskeleton of the 
tumor cells, a major change in the gross morphology from a 
solid, two dimensional state to a three dimensional substrate 
was noted. This morphological change was characterized 
by long, dendritic-like processes that displayed regions 
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of ruffling activity and filopodial protrusions and by down 
regulation of stress-fibers.[82] 
Thus, OBSC is an excellent technology to address a wide 
range of topics in primary brain tumor research, ranging from 
growth- and dissemination-promoting signaling, to the intricate 
interrelations between the tumor and its surrounding host tissue 
to the evaluation of efficaciousness of novel targeting strategies.
FUTURE PERSPECTIVES
Main emphasis for improving current in vitro technologies 
should be given to the cellular composition and the 
biophysical and chemical environment conditions under 
which the experiment is performed. The microenvironment 
of the in vivo location of the tumor and the composition of 
the neuronal and interstitial cells resident in this location 
should guide the choice of the components. At the single 
cell and population levels, molecular sensors for specific cell 
functions should be used for probing tumor cell behavior 
and therapeutic efficacy. Finally, an increased output 
should be strived for to enable pharmacological and genetic 
screening approaches for drug target identification. Thus, an 
organotypic environment, specific read-outs and the high 
throughput capability will be the three pillars of future in vitro 
approaches. A great potential lies in organotypic slice culture, 
and when this technology is combined with state-of-the-art 
microscopy, it will allow to reveal fundamental aspects of 
local tumor cell infiltration, the interaction of neuronal and 
brain interstitial cell populations with the tumor cells and the 
evaluation of the efficaciousness of novel treatments.
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